Results 101 to 110 of about 151,951 (312)

Survivin and Aurora Kinase A control cell fate decisions during mitosis

open access: yesMolecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir   +2 more
wiley   +1 more source

Transfer of Leachable Substances from Cross-Linked Peroxide Polyethylene (PEX-a) into Hemodialysis Water

open access: yesRevista Portuguesa de Nefrologia e Hipertensão, 2023
Faissal Tarrass, Meryem Benjelloun
doaj   +1 more source

EMM EMUS Observations of Hot Oxygen Corona at Mars: Radial Distribution and Temporal Variability [PDF]

open access: hybrid
Krishnaprasad Chirakkil   +18 more
openalex   +1 more source

Constraints on water activity at the Zhurong landing site in Utopia Planitia, Mars

open access: gold, 2023
ChengZheng Yong   +4 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Liquid Water Detection under the South Polar Layered Deposits of Mars—A Probabilistic Inversion Approach [PDF]

open access: gold, 2019
Sebastian Emanuel Lauro   +9 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy